Serum vascular adhesion protein-1 is increased in acute and chronic hyperglycemia
HY Li, JN Wei, MS Lin, DJ Smith, J Vainio, CH Lin… - Clinica chimica acta, 2009 - Elsevier
HY Li, JN Wei, MS Lin, DJ Smith, J Vainio, CH Lin, FT Chiang, SR Shih, CH Huang, MY Wu…
Clinica chimica acta, 2009•ElsevierBACKGROUND: The relationship between serum vascular adhesion protein-1 (VAP-1) and
plasma glucose in normal and drug-naïve type 2 diabetes subjects is unclear. We examined
if serum VAP-1 changed acutely to oral glucose loading and analyzed the relationship
between serum VAP-1, fasting plasma glucose (FPG), hemoglobin A1c, and type 2 diabetes.
METHODS: Adults without history of diabetes were included. Subjects taking anti-diabetic
drugs were excluded. Serum VAP-1 was analyzed by time-resolved immunofluorometric …
plasma glucose in normal and drug-naïve type 2 diabetes subjects is unclear. We examined
if serum VAP-1 changed acutely to oral glucose loading and analyzed the relationship
between serum VAP-1, fasting plasma glucose (FPG), hemoglobin A1c, and type 2 diabetes.
METHODS: Adults without history of diabetes were included. Subjects taking anti-diabetic
drugs were excluded. Serum VAP-1 was analyzed by time-resolved immunofluorometric …
BACKGROUND
The relationship between serum vascular adhesion protein-1 (VAP-1) and plasma glucose in normal and drug-naïve type 2 diabetes subjects is unclear. We examined if serum VAP-1 changed acutely to oral glucose loading and analyzed the relationship between serum VAP-1, fasting plasma glucose (FPG), hemoglobin A1c, and type 2 diabetes.
METHODS
Adults without history of diabetes were included. Subjects taking anti-diabetic drugs were excluded. Serum VAP-1 was analyzed by time-resolved immunofluorometric assay.
RESULTS
We recruited 333 subjects (186 females and 147 males), aged 56.1±11.6 y. After glucose challenge, serum VAP-1 rose significantly at 30 min (p<0.0001) and lasted until 2 h (p<0.0001). The change of serum VAP-1 between fasting and 30-min postload correlated inversely to the change of plasma insulin (r=−0.21, p=0.049). Fasting serum VAP-1 was associated with FPG in those with FPG ≥5.55 mmol/l (p=0.025) but not in those with FPG<5.55 mmol/l (p=NS). Fasting serum VAP-1 were higher in diabetic subjects (p=0.04) and correlated positively to hemoglobin A1c (r=0.18, p=0.002) after adjusting for age, gender, and waist circumference.
CONCLUSIONS
Serum VAP-1 is increased in both acute and chronic hyperglycemia. Whether serum VAP-1 is a good biomarker for hyperglycemia-associated complications merits further investigation.
Elsevier